Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 6/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025206 | 0.78 | MAPK1 (0.46) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL19995056 | 0.76 | MAPK1 (0.44) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL2635616 | 0.74 | MAPK1 (0.42) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL28505162 | 0.74 | MAPK1 (0.42) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL8910349 | 0.73 | MAPK1 (0.41) | MAPK1HPGDTK1TYMP | |
| SCHEMBL4342113 | 0.73 | TYMP (0.49) | MAPK1HPGDTK1TYMP | |
| SCHEMBL28402505 | 0.73 | TK1 (0.39) | MAPK1HPGDTK1TYMP | |
| SCHEMBL1092921 | 0.72 | MAPK1 (0.43) | MAPK1HPGDTK1TYMPALDH1A1 | |
| SCHEMBL6714052 | 0.72 | TK1 (0.57) | MAPK1HPGDTK1TYMP | |
| SCHEMBL6911384 | 0.72 | TYMP (0.44) | MAPK1HPGDTK1TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116453-A1 | Synthesis and methods of use pyrimidine analogues and derivatives | SPECTRUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20030055249-A1 | Synthesis and methods of use of pyrimidine analogues and derivatives | NEOTHERAPEUTICS, INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2003007963-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | NEOTHERAPEUTICS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055249-A1 | Synthesis and methods of use of pyrimidine analogues and derivatives | ATIC, SLC29A1, ABCG2 | MAPK1 1553/4885HPGD 263/4885TK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.